世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 非チロシンキナーゼ阻害剤の世界市場成長 2025-2031Global Non-Tyrosine Kinase Inhibitors Market Growth 2025-2031 世界の非チロシンキナーゼ阻害剤市場規模は、2025年の百万米ドルから2031年には百万米ドルに成長すると予測されている。 非チロシンキナーゼ阻害剤の米国市場は、2024年の百万米ドルから2031年には百万米ドルに... もっと見る
サマリー世界の非チロシンキナーゼ阻害剤市場規模は、2025年の百万米ドルから2031年には百万米ドルに成長すると予測されている。非チロシンキナーゼ阻害剤の米国市場は、2024年の百万米ドルから2031年には百万米ドルに増加すると予測され、2025年から2031年までの年平均成長率は%である。 非チロシンキナーゼ阻害剤の中国市場は、2024年の百万米ドルから2031年には百万米ドルに、2025年から2031年までの年平均成長率は％と推定される。 非チロシンキナーゼ阻害剤のヨーロッパ市場は、2025年から2031年までの年平均成長率%で、2024年の百万米ドルから2031年には百万米ドルに増加すると推定される。 非チロシンキナーゼ阻害剤の世界的な主要企業は、Roche、Eli Lilly、Novartis、Array BioPharma、Nerviano Medical Sciencesなどである。売上高では、2024年に世界の2大企業がほぼ％のシェアを占めている。 LPインフォメーション社の最新調査レポート「非チロシンキナーゼ阻害剤産業の予測」は、過去の売上高と2024年の世界全体の非チロシンキナーゼ阻害剤売上高に注目し、2025年から2031年までの予測非チロシンキナーゼ阻害剤売上高を地域別・市場分野別に包括的に分析しています。非チロシンキナーゼ阻害剤売上高を地域別、市場分野別、サブセクター別に分類し、世界の非チロシンキナーゼ阻害剤産業の詳細な分析を百万米ドル単位で提供します。 本インサイトレポートでは、世界の非チロシンキナーゼ阻害剤業界を包括的に分析し、製品区分、企業構成、売上高、市場シェア、最新動向、M&A活動などに関する主要動向を明らかにします。また本レポートでは、非チロシンキナーゼ阻害剤のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡を中心に、主要グローバル企業の戦略を分析し、加速する世界の非チロシンキナーゼ阻害剤市場におけるこれらの企業の独自の地位をより深く理解しています。 この調査レポートは、非チロシンキナーゼ阻害剤の世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測することで、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の非チロシンキナーゼ阻害剤の現状と将来の軌道について非常にニュアンスのある見解を提供します。 当レポートでは、非チロシンキナーゼ阻害剤市場の製品タイプ別、用途別、主要メーカー別、主要地域別および国別の包括的概要、市場シェア、成長機会を提示しています。 タイプ別セグメンテーション mTOR阻害剤 RAF/MEK阻害剤 CDK阻害剤 用途別セグメント 肝臓がん 呼吸器癌 脳腫瘍 その他 本レポートではまた、市場を地域別に分けています： 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ロシュ イーライリリー ノバルティス アレイ・バイオファーマ ネルビアーノ・メディカル・サイエンシズ ファイザー メルクKGaA アステックス・ファーマシューティカルズ シクラセル・ファーマシューティカルズ 第一三共 オンコノバ・セラピューティクス アストラゼネカ グラクソ・スミスクライン（GSK） カルナバイオサイエンス セルジーン・コーポレーション エタニティ・バイオサイエンス ジャスコ・ファーマシューティカルズ 本レポートで扱う主な質問 世界の非チロシンキナーゼ阻害薬市場の10年展望は？ 非チロシンキナーゼ阻害剤市場の成長を促進する要因は何か？ 市場別、地域別に最も急成長する技術は何か？ 非チロシンキナーゼ阻害剤の市場機会は最終市場規模によってどのように異なるのか？ 非チロシンキナーゼ阻害剤のタイプ別、用途別の内訳は？ 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales 2020-2031 2.1.2 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Geographic Region, 2020, 2024 & 2031 2.1.3 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Country/Region, 2020, 2024 & 2031 2.2 Non-Tyrosine Kinase Inhibitors Segment by Type 2.2.1 mTOR Inhibitors 2.2.2 RAF/MEK Inhibitors 2.2.3 CDK Inhibitors 2.3 Non-Tyrosine Kinase Inhibitors Sales by Type 2.3.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2025) 2.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2020-2025) 2.3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Type (2020-2025) 2.4 Non-Tyrosine Kinase Inhibitors Segment by Application 2.4.1 Liver Cancer 2.4.2 Respiratory Cancer 2.4.3 Brain Cancer 2.4.4 Others 2.5 Non-Tyrosine Kinase Inhibitors Sales by Application 2.5.1 Global Non-Tyrosine Kinase Inhibitors Sale Market Share by Application (2020-2025) 2.5.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Application (2020-2025) 2.5.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Application (2020-2025) 3 Global by Company 3.1 Global Non-Tyrosine Kinase Inhibitors Breakdown Data by Company 3.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Company (2020-2025) 3.1.2 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2020-2025) 3.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Company (2020-2025) 3.2.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Company (2020-2025) 3.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Company (2020-2025) 3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Company 3.4 Key Manufacturers Non-Tyrosine Kinase Inhibitors Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Non-Tyrosine Kinase Inhibitors Product Location Distribution 3.4.2 Players Non-Tyrosine Kinase Inhibitors Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Non-Tyrosine Kinase Inhibitors by Geographic Region 4.1 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Geographic Region (2020-2025) 4.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Geographic Region (2020-2025) 4.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Geographic Region (2020-2025) 4.2 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Country/Region (2020-2025) 4.2.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Country/Region (2020-2025) 4.2.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Country/Region (2020-2025) 4.3 Americas Non-Tyrosine Kinase Inhibitors Sales Growth 4.4 APAC Non-Tyrosine Kinase Inhibitors Sales Growth 4.5 Europe Non-Tyrosine Kinase Inhibitors Sales Growth 4.6 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales Growth 5 Americas 5.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country 5.1.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 5.1.2 Americas Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 5.2 Americas Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 5.3 Americas Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region 6.1.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region (2020-2025) 6.1.2 APAC Non-Tyrosine Kinase Inhibitors Revenue by Region (2020-2025) 6.2 APAC Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 6.3 APAC Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Non-Tyrosine Kinase Inhibitors by Country 7.1.1 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 7.1.2 Europe Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 7.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 7.3 Europe Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors by Country 8.1.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 8.1.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 8.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 8.3 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Non-Tyrosine Kinase Inhibitors 10.3 Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors 10.4 Industry Chain Structure of Non-Tyrosine Kinase Inhibitors 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Non-Tyrosine Kinase Inhibitors Distributors 11.3 Non-Tyrosine Kinase Inhibitors Customer 12 World Forecast Review for Non-Tyrosine Kinase Inhibitors by Geographic Region 12.1 Global Non-Tyrosine Kinase Inhibitors Market Size Forecast by Region 12.1.1 Global Non-Tyrosine Kinase Inhibitors Forecast by Region (2026-2031) 12.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue Forecast by Region (2026-2031) 12.2 Americas Forecast by Country (2026-2031) 12.3 APAC Forecast by Region (2026-2031) 12.4 Europe Forecast by Country (2026-2031) 12.5 Middle East & Africa Forecast by Country (2026-2031) 12.6 Global Non-Tyrosine Kinase Inhibitors Forecast by Type (2026-2031) 12.7 Global Non-Tyrosine Kinase Inhibitors Forecast by Application (2026-2031) 13 Key Players Analysis 13.1 Roche 13.1.1 Roche Company Information 13.1.2 Roche Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.1.4 Roche Main Business Overview 13.1.5 Roche Latest Developments 13.2 Eli Lilly 13.2.1 Eli Lilly Company Information 13.2.2 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.2.4 Eli Lilly Main Business Overview 13.2.5 Eli Lilly Latest Developments 13.3 Novartis 13.3.1 Novartis Company Information 13.3.2 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.3.4 Novartis Main Business Overview 13.3.5 Novartis Latest Developments 13.4 Array BioPharma 13.4.1 Array BioPharma Company Information 13.4.2 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.4.4 Array BioPharma Main Business Overview 13.4.5 Array BioPharma Latest Developments 13.5 Nerviano Medical Sciences 13.5.1 Nerviano Medical Sciences Company Information 13.5.2 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.5.4 Nerviano Medical Sciences Main Business Overview 13.5.5 Nerviano Medical Sciences Latest Developments 13.6 Pfizer 13.6.1 Pfizer Company Information 13.6.2 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.6.4 Pfizer Main Business Overview 13.6.5 Pfizer Latest Developments 13.7 Merck KGaA 13.7.1 Merck KGaA Company Information 13.7.2 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.7.4 Merck KGaA Main Business Overview 13.7.5 Merck KGaA Latest Developments 13.8 Astex Pharmaceuticals 13.8.1 Astex Pharmaceuticals Company Information 13.8.2 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.8.4 Astex Pharmaceuticals Main Business Overview 13.8.5 Astex Pharmaceuticals Latest Developments 13.9 Cyclacel Pharmaceuticals 13.9.1 Cyclacel Pharmaceuticals Company Information 13.9.2 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.9.4 Cyclacel Pharmaceuticals Main Business Overview 13.9.5 Cyclacel Pharmaceuticals Latest Developments 13.10 Daiichi Sankyo 13.10.1 Daiichi Sankyo Company Information 13.10.2 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.10.4 Daiichi Sankyo Main Business Overview 13.10.5 Daiichi Sankyo Latest Developments 13.11 Onconova Therapeutics 13.11.1 Onconova Therapeutics Company Information 13.11.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.11.4 Onconova Therapeutics Main Business Overview 13.11.5 Onconova Therapeutics Latest Developments 13.12 AstraZeneca 13.12.1 AstraZeneca Company Information 13.12.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.12.4 AstraZeneca Main Business Overview 13.12.5 AstraZeneca Latest Developments 13.13 GlaxoSmithKline (GSK) 13.13.1 GlaxoSmithKline (GSK) Company Information 13.13.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.13.4 GlaxoSmithKline (GSK) Main Business Overview 13.13.5 GlaxoSmithKline (GSK) Latest Developments 13.14 Carna Biosciences 13.14.1 Carna Biosciences Company Information 13.14.2 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.14.4 Carna Biosciences Main Business Overview 13.14.5 Carna Biosciences Latest Developments 13.15 Celgene Corporation 13.15.1 Celgene Corporation Company Information 13.15.2 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.15.4 Celgene Corporation Main Business Overview 13.15.5 Celgene Corporation Latest Developments 13.16 Eternity Bioscience 13.16.1 Eternity Bioscience Company Information 13.16.2 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.16.4 Eternity Bioscience Main Business Overview 13.16.5 Eternity Bioscience Latest Developments 13.17 Jasco Pharmaceuticals 13.17.1 Jasco Pharmaceuticals Company Information 13.17.2 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.17.4 Jasco Pharmaceuticals Main Business Overview 13.17.5 Jasco Pharmaceuticals Latest Developments 14 Research Findings and Conclusion
SummaryThe global Non-Tyrosine Kinase Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales 2020-2031 2.1.2 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Geographic Region, 2020, 2024 & 2031 2.1.3 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Country/Region, 2020, 2024 & 2031 2.2 Non-Tyrosine Kinase Inhibitors Segment by Type 2.2.1 mTOR Inhibitors 2.2.2 RAF/MEK Inhibitors 2.2.3 CDK Inhibitors 2.3 Non-Tyrosine Kinase Inhibitors Sales by Type 2.3.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2025) 2.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2020-2025) 2.3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Type (2020-2025) 2.4 Non-Tyrosine Kinase Inhibitors Segment by Application 2.4.1 Liver Cancer 2.4.2 Respiratory Cancer 2.4.3 Brain Cancer 2.4.4 Others 2.5 Non-Tyrosine Kinase Inhibitors Sales by Application 2.5.1 Global Non-Tyrosine Kinase Inhibitors Sale Market Share by Application (2020-2025) 2.5.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Application (2020-2025) 2.5.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Application (2020-2025) 3 Global by Company 3.1 Global Non-Tyrosine Kinase Inhibitors Breakdown Data by Company 3.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Company (2020-2025) 3.1.2 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2020-2025) 3.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Company (2020-2025) 3.2.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Company (2020-2025) 3.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Company (2020-2025) 3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Company 3.4 Key Manufacturers Non-Tyrosine Kinase Inhibitors Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Non-Tyrosine Kinase Inhibitors Product Location Distribution 3.4.2 Players Non-Tyrosine Kinase Inhibitors Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Non-Tyrosine Kinase Inhibitors by Geographic Region 4.1 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Geographic Region (2020-2025) 4.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Geographic Region (2020-2025) 4.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Geographic Region (2020-2025) 4.2 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Country/Region (2020-2025) 4.2.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Country/Region (2020-2025) 4.2.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Country/Region (2020-2025) 4.3 Americas Non-Tyrosine Kinase Inhibitors Sales Growth 4.4 APAC Non-Tyrosine Kinase Inhibitors Sales Growth 4.5 Europe Non-Tyrosine Kinase Inhibitors Sales Growth 4.6 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales Growth 5 Americas 5.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country 5.1.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 5.1.2 Americas Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 5.2 Americas Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 5.3 Americas Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region 6.1.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region (2020-2025) 6.1.2 APAC Non-Tyrosine Kinase Inhibitors Revenue by Region (2020-2025) 6.2 APAC Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 6.3 APAC Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Non-Tyrosine Kinase Inhibitors by Country 7.1.1 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 7.1.2 Europe Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 7.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 7.3 Europe Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors by Country 8.1.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025) 8.1.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025) 8.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025) 8.3 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Non-Tyrosine Kinase Inhibitors 10.3 Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors 10.4 Industry Chain Structure of Non-Tyrosine Kinase Inhibitors 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Non-Tyrosine Kinase Inhibitors Distributors 11.3 Non-Tyrosine Kinase Inhibitors Customer 12 World Forecast Review for Non-Tyrosine Kinase Inhibitors by Geographic Region 12.1 Global Non-Tyrosine Kinase Inhibitors Market Size Forecast by Region 12.1.1 Global Non-Tyrosine Kinase Inhibitors Forecast by Region (2026-2031) 12.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue Forecast by Region (2026-2031) 12.2 Americas Forecast by Country (2026-2031) 12.3 APAC Forecast by Region (2026-2031) 12.4 Europe Forecast by Country (2026-2031) 12.5 Middle East & Africa Forecast by Country (2026-2031) 12.6 Global Non-Tyrosine Kinase Inhibitors Forecast by Type (2026-2031) 12.7 Global Non-Tyrosine Kinase Inhibitors Forecast by Application (2026-2031) 13 Key Players Analysis 13.1 Roche 13.1.1 Roche Company Information 13.1.2 Roche Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.1.4 Roche Main Business Overview 13.1.5 Roche Latest Developments 13.2 Eli Lilly 13.2.1 Eli Lilly Company Information 13.2.2 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.2.4 Eli Lilly Main Business Overview 13.2.5 Eli Lilly Latest Developments 13.3 Novartis 13.3.1 Novartis Company Information 13.3.2 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.3.4 Novartis Main Business Overview 13.3.5 Novartis Latest Developments 13.4 Array BioPharma 13.4.1 Array BioPharma Company Information 13.4.2 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.4.4 Array BioPharma Main Business Overview 13.4.5 Array BioPharma Latest Developments 13.5 Nerviano Medical Sciences 13.5.1 Nerviano Medical Sciences Company Information 13.5.2 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.5.4 Nerviano Medical Sciences Main Business Overview 13.5.5 Nerviano Medical Sciences Latest Developments 13.6 Pfizer 13.6.1 Pfizer Company Information 13.6.2 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.6.4 Pfizer Main Business Overview 13.6.5 Pfizer Latest Developments 13.7 Merck KGaA 13.7.1 Merck KGaA Company Information 13.7.2 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.7.4 Merck KGaA Main Business Overview 13.7.5 Merck KGaA Latest Developments 13.8 Astex Pharmaceuticals 13.8.1 Astex Pharmaceuticals Company Information 13.8.2 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.8.4 Astex Pharmaceuticals Main Business Overview 13.8.5 Astex Pharmaceuticals Latest Developments 13.9 Cyclacel Pharmaceuticals 13.9.1 Cyclacel Pharmaceuticals Company Information 13.9.2 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.9.4 Cyclacel Pharmaceuticals Main Business Overview 13.9.5 Cyclacel Pharmaceuticals Latest Developments 13.10 Daiichi Sankyo 13.10.1 Daiichi Sankyo Company Information 13.10.2 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.10.4 Daiichi Sankyo Main Business Overview 13.10.5 Daiichi Sankyo Latest Developments 13.11 Onconova Therapeutics 13.11.1 Onconova Therapeutics Company Information 13.11.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.11.4 Onconova Therapeutics Main Business Overview 13.11.5 Onconova Therapeutics Latest Developments 13.12 AstraZeneca 13.12.1 AstraZeneca Company Information 13.12.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.12.4 AstraZeneca Main Business Overview 13.12.5 AstraZeneca Latest Developments 13.13 GlaxoSmithKline (GSK) 13.13.1 GlaxoSmithKline (GSK) Company Information 13.13.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.13.4 GlaxoSmithKline (GSK) Main Business Overview 13.13.5 GlaxoSmithKline (GSK) Latest Developments 13.14 Carna Biosciences 13.14.1 Carna Biosciences Company Information 13.14.2 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.14.4 Carna Biosciences Main Business Overview 13.14.5 Carna Biosciences Latest Developments 13.15 Celgene Corporation 13.15.1 Celgene Corporation Company Information 13.15.2 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.15.4 Celgene Corporation Main Business Overview 13.15.5 Celgene Corporation Latest Developments 13.16 Eternity Bioscience 13.16.1 Eternity Bioscience Company Information 13.16.2 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.16.4 Eternity Bioscience Main Business Overview 13.16.5 Eternity Bioscience Latest Developments 13.17 Jasco Pharmaceuticals 13.17.1 Jasco Pharmaceuticals Company Information 13.17.2 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications 13.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 13.17.4 Jasco Pharmaceuticals Main Business Overview 13.17.5 Jasco Pharmaceuticals Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート本レポートと同じKEY WORD（kinase）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2025/02/21 10:27 150.86 円 158.69 円 193.74 円 |
